secwatch.observer — SEC 8-K summary
======================================

Issuer:     MYRIAD GENETICS INC (MYGN)
CIK:        0000899923
Form:       8-K
Filed at:   2022-02-09T23:59:59+00:00
Accession:  0000899923-22-000014
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Myriad Genetics CSO Jerry Lanchbury retires; severance $782k plus equity acceleration
--------------------------------------------------------------------------------

- Jerry Lanchbury retired as Chief Scientific Officer effective Jan 14, 2022, will consult through Mar 31, 2022.
- Lump sum severance of $782,276.93; weekly consulting fee of $500; additional $45,401.67 possible at end.
- Unvested equity awards scheduled to vest within two years of transition are accelerated, with performance-based awards subject to conditions.
- Non-compete and non-solicitation covenants apply for 12 months after the consulting period.
- Eligible for 2021 annual bonus as determined by Compensation Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000014/0000899923-22-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899923/000089992322000014/mygn-20220207.htm
  HTML page:      https://secwatch.observer/filing/0000899923-22-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer